Review Article

Should We Consider Patients with Coexistent Hepatitis B or C Infection for Orthotopic Heart Transplantation?

Table 2

Studies correlating HBV/HCV infection and clinical outcomes in other solid organ transplantation processes.

AuthorCountryTransplanted organCohort sizeFollow-upMeasureOutcome

Roth et al., 2011 [15]USAKidney 10 yearsLong-term outcome of RTx in HCV+ patientsRTx confers a long-term survival benefit

Knoll et al., 1997 [16]USAKidney = 2053  
HCV+
RTx
Waiting list
2 yearsOutcomes in HCV+ RTx recipients to HCV+ ESRD patientsDecreased survival in HCV+ patients on waiting list compared to those who had RTx

Fabrizi et al., 2005 [17]ItalyKidney Outcome of RTx in HBV+ patientsIncreased mortality in HBV+ recipients than HBV− recipients

Reddy et al., 2011 [18]USAKidney = 75,861 
HBV+
HBV−   = 74,335
5 yearsPatient/graft survival in HBV+ recipientsPatient/graft survival in HBV+ was comparable to HBV− recipients

Sahi et al., 2007 [19]USALung
HCV+
3.2 yearsOutcome of lung transplant in HCV+ recipients compared to HCV− controlsNo significant difference in patient and graft survival

Hartwig et al., 2005 [20]USALung
HB group
HC group
Outcome of the use of HbcAb+ and HCVAb+ allograftsUse of HbcAb+ allografts in recipients with prior immunisation was safe

Dhillon et al., 2009 [21]USAHeart-lungHbcAb+
HbcAb−   = 13,233
5 yearsImpact of donor HbcAb+ status on outcomes of lung and heart-lung recipientsLungs and heart-lung allografts from HbcAb+ donors may be safely used

Singal et al., 2013 [22]USALiver = 546875 yearsOutcomes of liver transplant based on etiology of liver diseaseWorst outcome in HCV+, HCV+, and alcohol

Reddy and Everson 2013 [23]USALiver 60 weeksTreatment of HCV recurrence with protease inhibitor based therapyIntervention with protease based therapy is justified in HCV eradication

HBV: hepatitis B virus, ESRD: end-stage renal disease, HbcAb: hepatitis B core antibody, HCV: hepatitis C virus, RTX: renal transplantation, HCV Ab: hepatitis C antibody.